PE20000633A1 - THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY - Google Patents
THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITYInfo
- Publication number
- PE20000633A1 PE20000633A1 PE1999000522A PE00052299A PE20000633A1 PE 20000633 A1 PE20000633 A1 PE 20000633A1 PE 1999000522 A PE1999000522 A PE 1999000522A PE 00052299 A PE00052299 A PE 00052299A PE 20000633 A1 PE20000633 A1 PE 20000633A1
- Authority
- PE
- Peru
- Prior art keywords
- etil
- pyridin
- oxo
- tartrate
- salt
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010065687 Bone loss Diseases 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS (SERM) TAL COMO (-)-CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL)-5,6,7,8-TETRAHIDRONAFTALENO-2-OL O SU SAL D-TARTRATO; b)UN SECRETAGOGO DE LA HORMONA DE CRECIMIENTO TAL COMO 2-AMINO-N-(1(R)-(2,4-DIFLUORO-BENCILOXIMETIL)-2-OXO-2-(3-OXO-3a(R)-PIRIDIN-2-ILMETIL)-2-(2,2,2-TRIFLUORO-ETIL)-2,3,3a,4,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDIN-5-IL)-ETIL)-2-METIL-PROPIONAMIDA O SU SAL L-TARTRATO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA FRAGILIDAD MUSCULOESQUELETICA, OSTEOPOROSIS, OSTEOTOMIA, PERDIDA OSEA IDIOPATICA INFANTIL, PERDIDA OSEA ASOCIADA CON PERIODONTITIS, CURACION DE HUESO DESPUES DE UNA RECONSTRUCCION FACIAL, RECONSTRUCCION MAXILAR, RECONSTRUCCION MANDIBULARREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING a) A SELECTIVE MODULATOR OF THE ESTROGEN RECEPTOR (SERM) SUCH AS (-) - CIS-6-PHENYL-5- (4- (2-PYRROLIDIN-1-IL-ETOXY) -PHENIL ) -5,6,7,8-TETRAHYDRONAPHTHALENE-2-OL OR ITS D-TARTRATE SALT; b) A SECRETAGOG OF GROWTH HORMONE SUCH AS 2-AMINO-N- (1 (R) - (2,4-DIFLUORO-BENZYLOXIMETHYL) -2-OXO-2- (3-OXO-3a (R) -PYRIDIN -2-ILMETIL) -2- (2,2,2-TRIFLUORO-ETIL) -2,3,3a, 4,6,7-HEXAHIDRO-PIRAZOLO [4,3-c] PYRIDIN-5-IL) -ETIL ) -2-METHYL-PROPIONAMIDE OR ITS SALT L-TARTRATE. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF MUSCULOSKELETAL FRAGILITY, OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATIC BONE LOSS, BONE LOSS ASSOCIATED WITH PERIODONTITIS, BONE HEALING AFTER MAXIMUM RECONSTRUCTION, FACIAL RECONSTRUCTION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000633A1 true PE20000633A1 (en) | 2000-07-26 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000522A PE20000633A1 (en) | 1998-06-16 | 1999-06-11 | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (en) |
| JP (1) | JP2002518328A (en) |
| KR (1) | KR20010052817A (en) |
| CN (1) | CN1305378A (en) |
| AP (1) | AP9901581A0 (en) |
| AR (1) | AR018868A1 (en) |
| AU (1) | AU3342099A (en) |
| BG (1) | BG105128A (en) |
| BR (1) | BR9911357A (en) |
| CA (1) | CA2335112A1 (en) |
| CO (1) | CO5070586A1 (en) |
| EA (1) | EA200001189A1 (en) |
| GT (1) | GT199900083A (en) |
| HR (1) | HRP20000857A2 (en) |
| HU (1) | HUP0102395A2 (en) |
| ID (1) | ID26726A (en) |
| IL (1) | IL139587A0 (en) |
| IS (1) | IS5727A (en) |
| MA (1) | MA26648A1 (en) |
| NO (1) | NO20006381L (en) |
| OA (1) | OA11569A (en) |
| PA (1) | PA8472101A1 (en) |
| PE (1) | PE20000633A1 (en) |
| PL (1) | PL345064A1 (en) |
| SK (1) | SK18902000A3 (en) |
| TN (1) | TNSN99118A1 (en) |
| UY (1) | UY25557A1 (en) |
| WO (1) | WO1999065488A1 (en) |
| ZA (1) | ZA993973B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| JP2004507502A (en) * | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | Sustained release formulation for growth hormone secretagogue |
| EP1666033B1 (en) * | 2001-11-29 | 2008-12-31 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| ES2604943T3 (en) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Ghrelin receptor macrocyclic modulators and procedures for their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-05-03 EA EA200001189A patent/EA200001189A1/en unknown
- 1999-05-03 ID IDW20002604A patent/ID26726A/en unknown
- 1999-05-03 CN CN99807381A patent/CN1305378A/en active Pending
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/en not_active Ceased
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Ceased
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/en not_active Application Discontinuation
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/en unknown
- 1999-05-03 HR HR20000857A patent/HRP20000857A2/en not_active Application Discontinuation
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/en unknown
- 1999-05-03 PL PL99345064A patent/PL345064A1/en unknown
- 1999-05-03 IL IL13958799A patent/IL139587A0/en unknown
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/en active Pending
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/en unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/en not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/en not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/en unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/en not_active Application Discontinuation
- 1999-06-15 MA MA25622A patent/MA26648A1/en unknown
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/en unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/en unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/en unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/en unknown
- 2000-12-14 NO NO20006381A patent/NO20006381L/en not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID26726A (en) | 2001-02-01 |
| SK18902000A3 (en) | 2001-12-03 |
| HRP20000857A2 (en) | 2001-10-31 |
| IL139587A0 (en) | 2002-02-10 |
| JP2002518328A (en) | 2002-06-25 |
| PL345064A1 (en) | 2001-11-19 |
| KR20010052817A (en) | 2001-06-25 |
| NO20006381D0 (en) | 2000-12-14 |
| AR018868A1 (en) | 2001-12-12 |
| UY25557A1 (en) | 2001-01-31 |
| HUP0102395A2 (en) | 2001-11-28 |
| GT199900083A (en) | 2000-12-05 |
| EA200001189A1 (en) | 2001-06-25 |
| NO20006381L (en) | 2000-12-14 |
| BG105128A (en) | 2001-11-30 |
| IS5727A (en) | 2000-11-24 |
| PA8472101A1 (en) | 2000-09-29 |
| CO5070586A1 (en) | 2001-08-28 |
| AP9901581A0 (en) | 1999-06-30 |
| CN1305378A (en) | 2001-07-25 |
| WO1999065488A1 (en) | 1999-12-23 |
| EP1085867A1 (en) | 2001-03-28 |
| AU3342099A (en) | 2000-01-05 |
| TNSN99118A1 (en) | 2005-11-10 |
| BR9911357A (en) | 2001-03-13 |
| CA2335112A1 (en) | 1999-12-23 |
| OA11569A (en) | 2004-07-01 |
| MA26648A1 (en) | 2004-12-20 |
| ZA993973B (en) | 2000-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110767A (en) | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | |
| ES2069750T3 (en) | METHODS AND COMPOSITIONS FOR HEALING BONES. | |
| ECSP066313A (en) | DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS | |
| ECSP066315A (en) | DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS | |
| EA200100154A1 (en) | Benzo-cycloheptenes, method of their production, containing their pharmaceutical preparations and their use for the preparation of drugs | |
| AR023130A1 (en) | COMPOSITIONS TO PROMOTE GROWTH | |
| IL154888A (en) | Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis | |
| BR0315645A (en) | Actrib fusion polypeptides and their uses | |
| DE69727158D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SELF-CROSS-LINKED AND NON-SELF-CROSSLINKED HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES | |
| MXPA02005173A (en) | Remedies for diseases in association with decrease in bone mass. | |
| AR013001A1 (en) | DERIVATIVES OF PIPERAZINE, PROCEDURES TO PREPARE THEM, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS A MEDICINAL PRODUCT AND THE METHOD FOR TREATING DISEASES MEDIATED BY TACHININ. | |
| BR0100558A (en) | Compositions and methods for treating osteoporosis | |
| ATE112684T1 (en) | USE OF IGF-II TO TREAT BONE DISEASES. | |
| BRPI0417621A (en) | continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen for the treatment of conditions with low bone mass | |
| BR0310087A (en) | Hyaluronic acid injectable solid carriers for application of osteogenic proteins | |
| PE20000644A1 (en) | THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND PARATHYROID HORMONE | |
| BR0012951A (en) | Selective retinoid agonists | |
| BR0211932A (en) | Methods and compositions for oral administration of parathyroid hormone, pth | |
| PE20000633A1 (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| IT1170214B (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES | |
| AU2284001A (en) | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | |
| BRPI0407178A (en) | Osteogenic Pharmaceutical Composition | |
| MXPA04004236A (en) | METHOD FOR THE FORMATION OF IBUPROFEN CRYSTALS. | |
| BRPI0409818A (en) | compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds | |
| PE20000646A1 (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |